Soligenix announces formation of psoriasis medical advisory board

Phase 2a clinical study in mild-to-moderate psoriasis initiating  in december 2022 princeton, n.j. , oct. 25, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a medical advisory board (mab) to provide medical/clinical strategic guidance to the company as it advances the phase 2a clinical development of sgx302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.
SNGX Ratings Summary
SNGX Quant Ranking